What's Happening?
A recent national analysis published in JAMA indicates that approximately half of the men in the United States who underwent focal therapy for prostate cancer over the past decade fell outside the risk groups for which current treatment guidelines support
the procedure. The study, which analyzed data from 1,179,384 men aged 50 and older diagnosed with nonmetastatic prostate cancer between 2010 and 2023 at Commission on Cancer-accredited centers, found that 51% of the 15,672 men who received focal therapy had low-risk, high-risk, or very high-risk disease. The remaining 49% had intermediate-risk disease, the only category where guidelines suggest a potential role. Current American Urological Association (AUA) and American Society for Radiation Oncology (ASTRO) guidelines classify focal ablation as investigational for low- and intermediate-risk disease due to a lack of high-quality comparative data, and they recommend against its use for high-risk disease outside of a clinical trial. The technology used in focal therapy has also evolved, with cryotherapy decreasing from 79.8% of procedures in 2010 to 19.1% in 2023, while laser ablation increased from 14.6% to 45.8%.
Why It's Important?
This analysis highlights a significant discordance between clinical practice and established guidelines for prostate cancer treatment in the U.S. The widespread use of focal therapy outside recommended risk groups raises concerns about whether patients are receiving the most evidence-based care. For men with low-risk prostate cancer, active surveillance is generally the preferred approach, yet the study found consistent use of focal therapy in this group. Conversely, for high-risk patients, where guidelines strongly advise against focal ablation outside of clinical trials, a notable percentage still received the treatment. This mismatch could lead to patients undergoing more aggressive treatments than necessary for low-risk cancers, or receiving less effective treatment for high-risk cancers, potentially impacting long-term outcomes, side effects, and quality of life. The study also suggests that factors such as patient age, comorbidity burden, insurance type, and the type of facility (community vs. academic) may influence treatment decisions more than clinical guidelines, indicating potential disparities in care.
What's Next?
The findings underscore the need for increased adherence to established guidelines in prostate cancer treatment. Patients newly diagnosed with prostate cancer are encouraged to actively engage with their physicians to understand their specific risk group and the evidence supporting proposed treatments. Asking about the appropriateness of active surveillance for low-risk disease and whether focal procedures are part of a clinical trial or registry is crucial. Seeking a second opinion, particularly at an academic center, is also recommended, as prostate cancer often allows sufficient time for thorough consideration of treatment options. Future updates to AUA and ASTRO guidelines will likely incorporate accumulating data on focal therapy, and ongoing prospective studies are essential to provide the long-term oncologic and functional outcomes needed to solidify its role in prostate cancer management.
Beyond the Headlines
The study's implications extend beyond individual patient care, touching upon broader issues within the U.S. healthcare system. The observed deviation from guidelines suggests a potential gap in the dissemination and implementation of evidence-based practices, particularly in community settings. The shift in technology, with a decline in cryotherapy and a rise in laser ablation, indicates a dynamic landscape in medical innovation, but also emphasizes the importance of robust clinical trials to validate new methods before widespread adoption. The analysis also implicitly raises questions about the influence of marketing and patient demand for less invasive procedures, even when long-term efficacy data is still emerging. Addressing these systemic challenges will require concerted efforts from medical societies, healthcare providers, and policymakers to ensure that treatment decisions are consistently guided by the best available evidence, ultimately improving patient outcomes and optimizing healthcare resource allocation.
